Welcome to our dedicated page for The Oncology Institute SEC filings (Ticker: TOIIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncology Institute, Inc. files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its operations, governance, and securities, including its common stock (TOI) and redeemable warrants (TOIIW). On this page, you can review those SEC filings alongside AI-generated summaries designed to clarify key points for readers.
Current reports on Form 8-K offer insight into material events affecting the company. Recent 8-K filings have addressed topics such as quarterly financial results, updates to financial guidance and longer-term outlook, changes in the composition of the Board of Directors, and the appointment of new directors and committee chairs. These filings also document press releases related to leadership changes, investor presentations, and other corporate communications.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, which are referenced in the company’s press releases, contain more comprehensive discussions of risk factors, business operations, and financial statements. For a value-based oncology organization like The Oncology Institute, these periodic reports can include information about revenue sources such as patient services, dispensary activities, and capitation arrangements, as well as non-GAAP metrics like Adjusted EBITDA and Free Cash Flow that the company uses to evaluate performance.
In addition to these core filings, investors may consult proxy statements for details on director compensation and governance practices, and Forms 4 for information on insider transactions involving TOI common stock or related securities. This platform surfaces new filings as they become available from EDGAR and applies AI to highlight important sections, summarize complex disclosures, and help users navigate lengthy documents such as 10-Ks and 10-Qs.
By combining real-time access to SEC filings with AI-driven explanations, this page supports users who want to understand how The Oncology Institute describes its business, financial condition, and corporate developments in its official regulatory submissions.
The Oncology Institute reported higher revenue driven by dispensary growth but remained unprofitable and reduced debt while cash declined. Total operating revenue rose to $119.8 million for the quarter and $224.2 million for the six months ended June 30, 2025, up from $98.6 million and $193.2 million a year earlier, led by a sharp increase in dispensary sales to $62.6 million for the quarter. The company reduced long-term debt (net) to $75.0 million after a partial prepayment and raised gross proceeds of about $16.5 million in a private placement.
Despite revenue growth, TOI recorded operating losses and a net loss of $17.0 million for the quarter and $36.6 million for the six months. Cash and cash equivalents fell to $30.3 million from $49.7 million at year-end 2024, though management states it has sufficient liquidity for at least one year. Non-operating items included a $7.3 million increase in the fair value of conversion option derivative liabilities and elimination of marketable securities by June 30, 2025. The consolidated financials include significant consolidated VIE balances, including VIE liabilities of $284.1 million for which creditors lack recourse to TOI’s general credit.
The Oncology Institute, Inc. furnished a press release that discloses its financial results and additional financial information for the three months ended June 30, 2025. The filing states the press release is provided as Exhibit 99.1 and clarifies that the information is being furnished rather than filed under the Exchange Act, limiting certain legal liabilities. The report lists the company’s registered securities (common stock: TOI; redeemable warrants: TOIIW) on Nasdaq and identifies the company as an emerging growth company. No detailed financial tables or specific line-item results are included in the 8-K text itself; readers must refer to Exhibit 99.1 for the full figures.
The Oncology Institute, Inc. reported that director Richard Barasch resigned from the Board, effective August 12, 2025, and the company states his resignation was not due to any disagreement with the company on operations, policies or practices. Anne McGeorge will replace Mr. Barasch as Chair of the Board, signaling an immediate leadership transition at the board level. The company furnished a press release dated August 13, 2025 as Exhibit 99.1 under Regulation FD. The Form 8-K does not disclose financial statements, material transactions, or earnings information.
Form 4 snapshot: On 07/24/2025 Oncology Institute, Inc. (TOI) director Richard A. Barasch reported a Code J transaction—an inter-entity distribution rather than an open-market trade. RAB Ventures (controlled by Barasch) transferred 287,756 common shares to member Boro Partners Fund 1 in proportion to Boro’s beneficial interest. The shares were moved at $0 consideration and therefore do not signal buying or selling pressure.
After the distribution, Barasch continues to hold 2,635,881 TOI shares indirectly through LLC structures and maintains no direct holdings. He disclaims investment control over Boro and any beneficial ownership beyond his pecuniary interest.
No derivative securities were reported and there were no changes to direct insider ownership. Given the internal nature of the transfer, the filing is generally viewed as administrative and is unlikely to have a material impact on TOI’s share valuation.
Director Richard A. Barasch of The Oncology Institute reported significant warrant exercise transactions on June 17, 2025. Through RAB Ventures (DFP) LLC, Barasch executed a cashless exercise of Common Warrants for 679,224 shares at an exercise price of $1.198 per share.
Key transaction details:
- Net received 368,096 shares of common stock through the cashless exercise
- Issuer withheld 311,128 shares for payment based on fair market value of $2.6154 per share
- Fair value calculated using 5-day volume weighted average price
- Total beneficial ownership after transaction: 2,923,637 shares held indirectly through LLC
The transaction was executed under a special waiver agreement allowing cashless exercise despite registration status, and is exempt under Rule 16b-6. The warrants had an expiration date of March 26, 2030.
Form 4 overview: Director Richard A. Barasch of The Oncology Institute, Inc. (TOI) reported two transactions converting Series A Common Stock Equivalent Preferred Stock into common shares.
- 06/17/2025: 1,595 preferred shares converted into 159,500 common shares. Post-conversion direct common ownership: 1,935,141.
- 06/18/2025: 6,204 preferred shares converted into 620,400 common shares, held indirectly by Helen Barasch Family Trust #1. Post-conversion indirect common ownership: 2,555,541.
Each preferred share converts into 100 common shares and carries no cash consideration, so the economic stake remains unchanged; the filing simply reclassifies equity from preferred to common. No shares were sold, and the director’s aggregate reported common holdings now total approximately 4.49 million (direct + indirect) when combining both ownership lines.
Potential implications for investors:
- The conversion adds 779,900 new common shares to the public float, creating modest dilution for existing shareholders.
- Because the insider retained all shares, the action may signal continued long-term commitment rather than profit-taking.
- No 10b5-1 trading plan was indicated for these specific transactions, and no cash changed hands.
The filing is routine for a preferred-to-common conversion and does not disclose earnings, operational updates, or strategic shifts. Investors should monitor subsequent filings to see whether the newly issued common shares are held or eventually sold.
FAQ
What is the current stock price of The Oncology Institute (TOIIW)?
